

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5937797

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BOEHRINGER INGELHEIM INTERNATIONAL GMBH	11/11/2015
RECEIVING PARTY DATA	
Name:	CENTREXION THERAPEUTICS CORPORATION
Street Address:	509 SOUTH EXETER STREET
City:	BALTIMORE
State/Country:	MARYLAND
Postal Code:	21202
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16749412
CORRESPONDENCE DATA	
Fax Number:	(617)426-6567
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6177287100
Email:	BosPatents@Dechert.com, Christian.Stevenson@Dechert.com, Jane.Legere@Dechert.com
Correspondent Name:	DECHERT LLP
Address Line 1:	ONE INTERNATIONAL PLACE, 40TH FLOOR
Address Line 2:	100 OLIVER STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02110-2605
ATTORNEY DOCKET NUMBER:	399251-CNX-016C4 160872
NAME OF SUBMITTER:	CHRISTIAN P. STEVENSON
SIGNATURE:	/CHRISTIAN P. STEVENSON/
DATE SIGNED:	01/30/2020
Total Attachments: 15	
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page1.tif	
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page2.tif	
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page3.tif	
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page4.tif	

source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page5.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page6.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page7.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page8.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page9.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page10.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page11.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page12.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page13.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page14.tif
source=CNX_016C4_Assignment_Boehringer_to_Centrexion#page15.tif

PATENT ASSIGNMENT

THIS ASSIGNMENT is made on November 11, 2015 between

Boehringer Ingelheim International GmbH ("BII"), a German limited liability company, with offices at Binger Straße 173, 55216 Ingelheim am Rhein, Germany

and

Centrexion Therapeutics Corporation ("CENTREXION"), a Delaware Corporation, with offices at 509 South Exeter Street, Baltimore, Maryland 21202, U.S.A

WHEREAS BII owns and controls certain patents and patent applications related to SSTR4 agonists, CCR2 antagonists and CB2 agonists.

NOW THEREFORE in consideration of the premises contained herein and for other valuable consideration that has been exchanged, CENTREXION requests and the BII HEREBY ASSIGNS to CENTREXION, who accepts, the Patents (which are the patents and patent applications listed on the attached Annex I and all other patents and patent applications in any country that (i) claim priority to a patent or patent application listed on the attached Annex I or (ii) have a common priority with a patent or patent application listed on the attached Annex I), all rights to claim priority from any of the Patents, all the right, title and interest therein and to all inventions disclosed therein, and all the rights, powers and privileges conferred on the proprietor thereof by the grant of the Patents, including the right to sue for damages and other remedies in respect of any infringement of the Patents which may have occurred prior to the date hereof TO HOLD the same unto the Assignee absolutely.

AND BII hereby gives explicit consent to CENTREXION to register and record the transfer of ownership right with the respective intellectual property offices worldwide.

In consideration for the above assignment, the CENTREXION has paid to BII the amount of EUR 1 (+ VAT, if applicable), receipt of which is acknowledged by BII.

This Agreement shall be governed by and construed in accordance with German law.

EXECUTED the date and year first above written


Ingelheim, November 11, 2015

Boehringer Ingelheim International GmbH

ppa.

ppa.

by



Dr. Elke Simon


Dorothee Schwall-Ruddolph

- Authorized Signatories -

h

STRUCTURE OF THE PATENT
EXAMINATION REPORT AND REPLY TO THE EXAMINATION REPORT

Baltimore, November 11, 2015
Centrexion Therapeutics Corporation

by 

h

Annex 1

Patent portfolio of the SSTR4 program

Patent Family: P01-2930

Title: New Somatostatin receptor subtype 4 (SSTR4) agonists

Country / Docket	Filing date	Application no.	Publication no.	Status
Argentina P01-2930/AR/1	16.05.2014	140101981		With letter dated 18 August 2015 local attorney is instructed to allow application to lapse.
Australia P01-2930/AU/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
Brazil P01-2930/BR/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
Canada P01-2930/CA/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
Chile P01-2930/CL/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
China P01-2930/CN/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
Eurasia P01-2930/EA/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
Europe P01-2930/EP/1 (Prio application; abandoned)	17.05.2013	13168224.7		lapsed
Gulf Cooperation Council P01-2930/GC/1	18.05.2014	27176		With letter dated 18 August 2015 local attorney is instructed to allow application to lapse.
Israel P01-2930/IL/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
India P01-2930/IN/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		

Jordan P01-2930/JO/1	18.05.2014	165-2014		With letter dated 18 August 2015 local attorney is instructed to allow application to lapse.
Japan P01-2930/JP/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
South Korea P01-2930/KR/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
Mexico P01-2930/MX/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
New Zealand P01-2930/NZ/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
Philippines P01-2930/PH/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
Pakistan P01-2930/PK/1	15.05.2014	371-2014		With letter dated 18 August 2015 local attorney is instructed to allow application to lapse.
Taiwan P01-2930/TW/1	16.05.2014	103117405		With letter dated 18 August 2015 local attorney is instructed to allow application to lapse.
Ukraine P01-2930/UA/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		
United States P01-2930/US/1	12.05.2014	14/275879	US 2014-0343065 A1	pending
Uruguay P01-2930/UY/1	16.05.2014	35572		With letter dated 18 August 2015 local attorney is instructed to allow application to lapse.
Venezuela P01-2930/VE/1	16.05.2014	2014-000616		With letter dated 18 August 2015 local attorney is instructed to allow application to lapse.
International P01-2930/WO/1	15.05.2014	PCT/EP2014059905	WO2014/184275	pending
South Africa P01-2930/ZA/1 as derived from P01-2930/WO/1	t.b.d.	t.b.d.		

Patent Family: P01-3140

15175285.4
15175285.4

Country / Docket	Filing date	Application no.	Publication no.
Europe P01-3140/EP/1 (Prio application; abandoned)	03.07.2015	15175285.4	

Patent portfolio of the CCR2 program

Patent family P01-2473

Title: CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR
 ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA
 AND COPD

Country / Docket	Application date	Application number	Publication number	Patent number
Austria P01-2473/AT/1	17.12.2009	09775212.5	EP2379525	EP2379525
Australia P01-2473/AU/1	17.12.2009	2009327127	WO2010070032	
Belgium P01-2473/BE/1	17.12.2009	09775212.5	EP2379525	EP2379525
Brazil P01-2473/BR/1	17.12.2009	0923051-3	WO2010070032	
Canada P01-2473/CA/1	17.12.2009	2747677	WO2010070032	
Switzerland P01-2473/CH/1	17.12.2009	09775212.5	EP2379525	EP2379525
Chile P01-2473/CL/1	17.12.2009	1322-2011	WO2010070032	
China P01-2473/CN/1	17.12.2009	200980150778.8	WO2010070032	200980150778.8
China P01-2473/CN/2	17.12.2009	201310682370.3	CN103724328A	
Germany P01-2473/DE/1	17.12.2009	09775212.5	EP2379525	602009032547.7
Denmark P01-2473/DK/1	17.12.2009	09775212.5	EP2379525	EP2379525
Eurasia P01-2473/EA/1	17.12.2009	201100942	WO2010070032	20548
Europe P01-2473/EP/1	19.12.2008	08172336.3		
Europe P01-2473/EP/2	15.05.2009	09160416.5		
Europe P01-2473/EP/3	17.12.2009	09775212.5	EP2379525	EP2379525
Europe P01-2473/EP/4	17.12.2009	14177922.3	EP2816040	
Spain P01-2473/ES/1	17.12.2009	09775212.5	EP2379525	EP2379525
France P01-2473/FR/1	17.12.2009	09775212.5	EP2379525	EP2379525
United Kingdom P01-2473/GB/1	17.12.2009	09775212.5	EP2379525	EP2379525

Country / Docket	Application date	Application number	Publication number	Patent number
Hungary P01-2473/HU/1	17.12.2009	09775212.5	EP2379525	E09775212
Israel P01-2473/IL/1	17.12.2009	212605	WO2010070032	
India P01-2473/IN/1	17.12.2009	4652-DELNP-2011	WO2010070032	
Italy P01-2473/IT/1	17.12.2009	09775212.5	EP2379525	EP2379525
Japan P01-2473/JP/1	17.12.2009	2011-541435	WO2010070032	
Japan P01-2473/JP/2	17.12.2009	2014-080374	2014-141573	5686916
South Korea P01-2473/KR/1	17.12.2009	10-2011-7014060	WO2010070032	
Mexico P01-2473/MX/1	17.12.2009	2011-005150	WO2010070032	319314
Netherlands P01-2473/NL/1	17.12.2009	09775212.5	EP2379525	EP2379525
New Zealand P01-2473/NZ/1	17.12.2009	592723	WO2010070032	592723
Philippines P01-2473/PH/1	17.12.2009	1-2011-501257	WO2010070032	
Poland P01-2473/PL/1	17.12.2009	09775212.5	EP2379525	EP2379525
Russian Federation P01-2473/RU/1	17.12.2009	201100942	WO2010070032	20548
Sweden P01-2473/SE/1	17.12.2009	09775212.5	EP2379525	EP2379525
Turkey P01-2473/TR/1	17.12.2009	09775212.5	EP2379525	TR201511833T4
United States P01-2473/US/1	17.12.2009	13/140591	US 2012-0053164 A1	
United States P01-2473/US/2	17.12.2009	13/949696	US 2013-0324517 A1	8835440
United States P01-2473/US/3	17.12.2009	14/445137	US 2014-0336374 A1	9067951
International P01-2473/WO/1	17.12.2009	PCT/EP2009067378	WO2010070032	
South Africa P01-2473/ZA/1	17.12.2009	2011-03158	WO2010070032	2011-03158

Patent family P01-2573

Title: New CCR2 receptor antagonists and uses thereof

Country / Docket	Application date	Application number	Publication number	Patent number
Albania P01-2573/AL/1	13.12.2010	2014-292	EP2513093	4892
ARIPO P01-2573/AP/1	13.12.2010	2012-006276	WO2011/073154	3170
Argentina P01-2573/AR/1	16.12.2010	100104699		
Austria P01-2573/AT/1	13.12.2010	10796336.5	EP2513093	2513093
Australia P01-2573/AU/1	13.12.2010	2010332969	WO2011/073154	2010332969
Bosnia and Herzegovina P01-2573/BA/1	13.12.2010	E01512	EP2513093	2513093
Belgium P01-2573/BE/1	13.12.2010	10796336.5	EP2513093	2513093
Bulgaria P01-2573/BG/1	13.12.2010	10796336.5	EP2513093	BG/EP2513093
Brazil P01-2573/BR/1	13.12.2010	112012015873-2	WO2011/073154	
Botswana P01-2573/BW/1	13.12.2010	2012-006276	WO2011/073154	3170
Canada P01-2573/CA/1	13.12.2010	2782464	WO2011/073154	
Switzerland P01-2573/CH/1	13.12.2010	10796336.5	EP2513093	2513093
Chile P01-2573/CL/1	13.12.2010	01311-2012	WO2011/073154	51157
China P01-2573/CN/1	13.12.2010	201080057415.2	WO2011/073154	ZL201080057415.2
Colombia P01-2573/CO/1	13.12.2010	12-101565	WO2011/073154	
Cyprus P01-2573/CY/1	13.12.2010	10796336.5	EP2513093	2513093
Czech Republic P01-2573/CZ/1	13.12.2010	10796336.5	EP2513093	2513093
Germany P01-2573/DE/1	13.12.2010	10796336.5	EP2513093	602010018608.3
Denmark P01-2573/DK/1	13.12.2010	10796336.5	EP2513093	2513093

Country / Docket	Application date	Application number	Publication number	Patent number
Algeria P01-2573/DZ/1	13.12.2010	120505	WO2011/073154	
Eurasia P01-2573/EA/1	13.12.2010	201200876	WO2011/073154	
Ecuador P01-2573/EC/1	13.12.2010	12-12010	WO2011/073154	
Estonia P01-2573/EE/1	13.12.2010	10796336.5	EP2513093	2513093
Egypt P01-2573/EG/1	13.12.2010	2012-1047	WO2011/073154	
Europe P01-2573/EP/1	17.12.2009	09179555.9		
Europe P01-2573/EP/2	12.05.2010	10162621.6		
Europe P01-2573/EP/3	13.12.2010	10796336.5	EP2513093	2513093
Europe P01-2573/EP/4	13.12.2010	14177921.5	EP2813503	
Spain P01-2573/ES/1	13.12.2010	10796336.5	EP2513093	2513093

Finland P01-2573/FI/1	13.12.2010	10796336.5	EP2513093	2513093
France P01-2573/FR/1	13.12.2010	10796336.5	EP2513093	2513093
United Kingdom P01-2573/GB/1	13.12.2010	10796336.5	EP2513093	2513093
Georgia 01-2573/GE/1	13.12.2010	12789-01-12	WO2011/073154	12789-01-12
Greece P01-2573/GR/1	13.12.2010	10796336.5	EP2513093	3084695
Hong Kong P01-2573/HK/1	13.12.2010	13105048.6	WO2011/073154	
Croatia P01-2573/HR/1	13.12.2010	10796336.5	EP2513093	P20141143
Hungary P01-2573/HU/1	13.12.2010	10796336.5	EP2513093	E022161
Indonesia P01-2573/ID/1	13.12.2010	201202271	WO2011/073154	36279
Ireland P01-2573/IE/1	13.12.2010	10796336.5	EP2513093	2513093
Israel P01-2573/IL/1	13.12.2010	219421	WO2011/073154	

India P01-2573/IN/1	13.12.2010	4734-DELNP-2012	WO2011/073154	
Iceland P01-2573/IS/1	13.12.2010	10796336.5	EP2513093	2513093

Country / Docket	Application date	Application number	Publication number	Patent number
Italy P01-2573/IT/1	13.12.2010	10796336.5	EP2513093	502014000002687
Japan P01-2573/JP/1	13.12.2010	2012-543667	WO2011/073154	5632014
Kenya P01-2573/KE/1	13.12.2010	2012-006276	WO2011/073154	3170
South Korea P01-2573/KR/1	13.12.2010	10-2012-7014412	WO2011/073154	10-1530234
Kosovo P01-2573/KS/1	13.12.2010	10796336.5	EP2513093	2014-108
Liberia P01-2573/LR/1	13.12.2010	2012-006276	WO2011/073154	3170
Lithuania P01-2573/LT/1	13.12.2010	10796336.5	EP2513093	2513093
Luxembourg P01-2573/LU/1	13.12.2010	10796336.5	EP2513093	2513093
Latvia P01-2573/LV/1	13.12.2010	10796336.5	EP2513093	2513093

Morocco P01-2573/MA/1	13.12.2010	34961	WO2011/073154	33818
Monaco P01-2573/MC/1	13.12.2010	10796336.5	EP2513093	2513093
Montenegro P01-2573/ME/1	13.12.2010	2014-106	EP2513093	2014-106
Macedonia P01-2573/MK/1	13.12.2010	2014-380	EP2513093	2513093
Malta P01-2573/MT/1	13.12.2010	10796336.5	EP2513093	2513093
Mexico P01-2573/MX/1	13.12.2010	2012-006964	WO2011/073154	312407
Mexico P01-2573/MX/2	13.12.2010	2013-008863		
Malaysia P01-2573/MY/1	13.12.2010	2012002736	WO2011/073154	
Mozambique P01-2573/MZ/1	13.12.2010	2012-006276	WO2011/073154	3170
Namibia P01-2573/NA/1	13.12.2010	2012-006276	WO2011/073154	3170
Nigeria P01-2573/NG/1	13.12.2010	2012-272	WO2011/073154	

Netherlands P01-2573/NL/1	13.12.2010	10796336.5	EP2513093	2513093
Norway P01-2573/NO/1	13.12.2010	10796336.5	EP2513093	2513093
New Zealand P01-2573/NZ/1	13.12.2010	599770	WO2011/073154	599770

Country / Docket	Application date	Application number	Publication number	Patent number
OAPI P01-2573/OA/1	13.12.2010	1201200236	WO2011/073154	15959
Peru P01-2573/PE/1	13.12.2010	000827-2012	WO2011/073154	
Philippines P01-2573/PH/1	13.12.2010	1-2012-S01215	WO2011/073154	
Pakistan P01-2573/PK/1	14.12.2010	1045-2010		
Poland P01-2573/PL/1	13.12.2010	10796336.5	EP2513093	2513093
Portugal P01-2573/PT/1	13.12.2010	10796336.5	EP2513093	2513093
Romania P01-2573/RO/1	13.12.2010	10796336.5	EP2513093	2513093
Serbia P01-2573/RS/1	13.12.2010	2014-0526	EP2513093	53555
Sweden P01-2573/SE/1	13.12.2010	10796336.5	EP2513093	2513093
Singapore P01-2573/SG/1	13.12.2010	201204412-9	WO2011/073154	
Slovenia P01-2573/SI/1	13.12.2010	10796336.5	EP2513093	2513093
Slovakia P01-2573/SK/1	13.12.2010	10796336.5	EP2513093	E17475
Thailand P01-2573/TH/1	13.12.2010	1201002897	126515	
Tunisia P01-2573/TN/1	13.12.2010	2012/0300	WO2011/073154	
Turkey P01-2573/TR/1	13.12.2010	10796336.5	EP2513093	TR201414105T4
Taiwan P01-2573/TW/1	16.12.2010	99144272	I473800	I473800
United Republic of Tanzania P01-2573/TZ/1	13.12.2010	2012-006276	WO2011/073154	3170
Ukraine P01-2573/UA/1	13.12.2010	a201208480	WO2011/073154	107820
United States P01-2573/US/1	16.12.2010	12/969745	US 2012-0004252 A1	8765949
United States P01-2573/US/2	16.12.2010	14/260552	US 2014-0235661 A1	
Uruguay P01-2573/UY/1	16.12.2010	33109		
Venezuela P01-2573/VE/1	15.12.2010	2010-001979		
Vietnam P01-2573/VN/1	13.12.2010	1-2012-02065	WO2011/073154	

Country / Docket	Application date	Application number	Publication number	Patent number
P01-2573/VN/1				
International P01-2573/WO/2	13.12.2010	PCT/EP2010069549	WO2011/073154	
South Africa P01-2573/ZA/1	13.12.2010	2012-03195	WO2011/073154	

Patent family P01-3139

Country / Docket	Application date	Application number	Publication number	Patent number
Europe P01-3139/EP/1	02 July 2015	15175066.8		

Patent portfolio of the CB2 program

Patent family P01-2927

Title: NOVEL(CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES

Country / Docket	Application date	Application number	Publication number	Patent number
Europe P01-2927/EP/1 (Prio application; abandoned)	17.05.2013	13168165.2	EP2803668	
United States P01-2927/US/1	15.05.2014	14/278064		8,865,744
international P01-2927/WO/1	16.05.2014	PCT/EP2014060033	WO2014/184327	
Australia P01-2927/AU/1 as derived from P01- 2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
Brazil P01-2927/BR/1 as derived from P01- 2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
Canada P01-2927/CA/1 as derived from P01- 2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
Chile P01-2927/CL/1 as derived from P01- 2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
China P01-2927/CN/1 as derived from P01- 2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
Eurasia P01-2927/EA/1 as derived from P01- 2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
Israel P01-2927/IL/1 as derived from P01- 2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
India P01-2927/IN/1 as derived from P01- 2927/WO/1	t.b.d.	t.b.d.	t.b.d.	

Country / Docket	Application date	Application number	Publication number	Patent number
Japan P01-2927/JP/1 as derived from P01-2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
South Korea P01-2927/KR/1 as derived from P01-2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
Mexico P01-2927/MX/1 as derived from P01-2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
New Zealand P01-2927/NZ/1 as derived from P01-2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
Philippines P01-2927/PH/1 as derived from P01-2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
Ukraine P01-2927/UA/1 as derived from P01-2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
United States P01-2927/US/2 as derived from P01-2927/WO/1	t.b.d.	t.b.d.	t.b.d.	
South Africa P01-2927/ZA/1 as derived from P01-2927/WO/1	t.b.d.	t.b.d.	t.b.d.	